01st week of 2011 patent applcation highlights part 38 |
Patent application number | Title | Published |
20110003707 | Highly Sensitive Biomarker Panels - Cardiovascular disease, e.g., congestive heart failure, is often first diagnosed after the onset of clinical symptoms, eliminating potential for early intervention. The invention provides a multi-marker immunoassay, including cardiac pathology and vascular inflammation biomarkers, yielding a more sensitive assay for early detection of CHF in plasma. A panel consisting of cardiac pathology (cTnI, BNP) and vascular inflammation (IL-6, TNFα, IL-17a) biomarkers provided a sensitivity of 94% for association with CHF. | 2011-01-06 |
20110003708 | BIOMARKERS FOR THE PREDICTION OF RENAL INJURY - The present invention relates to means and methods for predicting the onset of renal injury based on measuring the expression of polynucleotides and proteins, particularly on measuring the expression of sets of novel as well as known polynucleotides and proteins, and to kits utilizing same. | 2011-01-06 |
20110003709 | REAGENTS AND METHODS FOR USE IN CANCER DIAGNOSIS, CLASSIFICATION AND THERAPY - Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer. | 2011-01-06 |
20110003710 | SELECTIN LIGANDS USEFUL IN THE DIAGNOSIS AND TREATMENT OF CANCER - The present invention provides methods and compositions useful in the diagnosis and treatment of cancer. More specifically, the present invention provides compositions and methods of use comprising a targeting composition comprising a solid substrate, an antibody composition, and optionally a chemotherapeutic agent. | 2011-01-06 |
20110003711 | CELL LINES EXPRESSING GABA RECEPTOR AND METHODS USING THEM - The invention relates to Gamma-aminobutyric acid receptors (GABA receptors) as well as cells and cell lines stably expressing a GABA receptor. The invention includes cell lines that express various subunit combinations of GABA receptors. The GABA receptor- and GABA receptor subunit-expressing cell lines are highly sensitive, physiologically relevant and produce consistent results. The invention further provides methods of making such cells and cell lines. The GABA receptor- and GABA receptor subunit-expressing cells and cell lines provided herein are useful in identifying modulators of GABA receptors. | 2011-01-06 |
20110003712 | Methods, Kits and Compositions for the Identification of Nucleic Acids Electrostatically Bound to Matrices - This invention pertains to methods, kits and compositions suitable for the detection, identification and/or quantitation of nucleic acids which are electrostatically immobilized to matrices using non-nucleotide probes which sequence specifically hybridize to one or more target sequences of the nucleic acid but do not otherwise substantially interact with the matrix. Once the nucleic acid is immobilized, the detectable non-nucleotide probe/target sequence complex, formed before or after the immobilization of the nucleic acid, can be detected, identified or quantitated under a wide range of assay conditions as a means to detect, identify or quantitate the target sequence in the sample. Because it is reversibly bound, the non-nucleotide probe/target sequence can optionally be removed from the matrix for detecting, identifying or quantitating the target sequence in the sample. Because the non-nucleotide probe/target sequence is protected against degradation, it is another advantage of this invention that the sample can be treated with enzymes which degrade sample components, either before or after the nucleic acid is bound to the matrix, in order to “clean up” the sample (e.g. a complex biological sample such as a cell lysate) and thereby improve the detection, identification or quantitation of the target sequence in the sample. The methods, kits and compositions of this invention are therefore particularly well suited for the analysis, and particularly single point mutation analysis, in a particle assay, in an array assay, in a nuclease digestion/protection assay and/or in a line assay format. When utilized in combination with non-nucleotide “Beacon” probes, the invention is particularly well suited for use in a self-indicating assay format. | 2011-01-06 |
20110003713 | siRNA targeting apolipoprotein B (APOB) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, composition, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB. | 2011-01-06 |
20110003714 | siRNA Targeting Beta Secretase (BACE) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for BACE. | 2011-01-06 |
20110003715 | METHODS FOR DETECTION AND QUANTIFICATION OF ANALYTES IN COMPLEX MIXTURES - The invention provides a diverse population of uniquely labeled probes, containing about thirty or more target specific nucleic acid probes each attached to a unique label bound to a nucleic acid. Also provided is a method of producing a population of uniquely labeled nucleic acid probes. The method consists of (a) synthesizing a population of target specific nucleic acid probes each having a different specifier; (b) synthesizing a corresponding population of anti-genedigits each having a unique label, the population having a diversity sufficient to uniquely hybridize to genedigits within the specifiers, and (c) hybridizing the populations of target nucleic acid probes to the anti-genedigits, to produce a population in which each of the target specific probes is uniquely labeled. Also provided is a method of detecting a nucleic acid analyte. The method consists of (a) contacting a mixture of nucleic acid analytes under conditions sufficient for hybridization with a plurality of target specific nucleic acid probes each having a different specifier; (b) contacting the mixture under conditions sufficient for hybridization with a corresponding plurality of anti-genedigits each having a unique label, the plurality of anti-genedigits having a diversity sufficient to uniquely hybridize to genedigits within the specifiers, and (c) uniquely detecting a hybridized complex between one or more analytes in the mixture, a target specific probe, and an anti-genedigit. | 2011-01-06 |
20110003716 | ANTIREFLECTIVE COATINGS FOR HIGH-RESOLUTION PHOTOLITHOGRAPHIC SYNTHESIS OF DNA ARRAY - The present invention provides an array of polymers and methods of forming arrays of polymers by providing a substrate having a first layer including one or more dielectric coatings on a solid support and a second layer including a plurality of polymers disposed on the first layer. The invention also provides methods for forming an array of polymers on a substrate using light-directed synthesis by providing a substrate having a first layer including one or more dielectric coatings on a solid support, derivatizing the first layer by contacting the first layer with a silanation reagent, and a second layer disposed on said first layer wherein the second layer includes functional groups protected with a photolabile protecting group. | 2011-01-06 |
20110003717 | MICROTITRE PLATE - A microtitre plate with wells having transparent bottoms, wherein the microtitre plate includes at least one physical deformation between at least two adjacent wells. The physical deformations may have the shape of e.g. a channel, a ridge, a hole, a slit or a step. | 2011-01-06 |
20110003718 | SELF-SENSING ARRAY OF MICROCANTILEVERS CHEMICAL DETECTION - The invention provides a chemical detection system for detecting at least one target chemical species, including a self-sensed cantilevered probe array having a plurality of self-sensed cantilevered probes, at least one chemical-sensitive coating material applied to at least one cantilevered probe in the cantilevered probe array, and an interface circuit that is coupled to the cantilevered probe array. At least one cantilevered probe in the cantilevered probe array exhibits a shifted cantilevered probe response when the cantilevered probe array is exposed to the target chemical species and the interface circuit actuates the cantilevered probe. A handheld chemical detection system and a method of operation are also disclosed. | 2011-01-06 |
20110003719 | POLYMER-CONTAINING COMPOSITION, ITS PREPARATION AND USE - Process for the preparation of a polymer-containing composition comprising the steps of: a) preparing a mixture of at least one cyclic monomer selected from glycolide and lactide and a layered double hydroxide comprising as charge-balancing anions 10 to 100% of an organic anion and 0 to 90% of hydroxide, based on the total amount of charge-balancing anions, and b) polymerising said monomer, optionally in the presence of a polymerisation initiator or catalyst. | 2011-01-06 |
20110003720 | CONTROLLING THE STABILITY OF WATER IN WATER EMULSIONS - This invention relates to compositions and methods of treating a surface in contact with a wellbore and/or a subterranean formation penetrated by a well bore, comprising forming a treatment composition comprising a rheological polymer, a partitioning agent, and a liquid medium; and injecting the treatment fluid into the well bore, wherein the treatment composition forms a heterogeneous mixture comprising a dispersed rheological polymer-rich phase and a partitioning agent-rich phase, and wherein the stability of the heterogeneous mixture is controlled by introducing a stability control agent. This invention relates to compositions and methods for forming a water in water emulsion, comprising a rheological polymer, a partitioning agent, a liquid medium; and a stability control agent, wherein the emulsion is a heterogeneous mixture comprising a dispersed rheological polymer-rich phase and a partitioning agent-rich phase. | 2011-01-06 |
20110003721 | CARBON NANOPARTICLE-CONTAINING NANOFLUID - The present invention relates to compositions of a nanofluid, which comprises a thermal transfer fluid and carbon nanoparticles. The nanofluid may be hydrophilic nanofluids, such as a coolant, or hydrophobic nanofluids, such as nanolubricants or nanogreases. In particular, the present invention provides a homogenous hydrophilic nanofluid, which contains soluble carbon nanotubes in the hydrophilic thermal transfer fluid. The present invention also provides a nanogrease, which is a sustainable dispersion of solid carbon nanotubes in a hydrophobic thermal transfer fluid. The solid carbon nanotubes function as both as a thickener to modulate viscosity and as a solid heat transfer medium to enhance thermal conductivity and high temperature resistance. | 2011-01-06 |
20110003722 | EXTENDED DRAIN DIESEL LUBRICANT FORMULATIONS - A method for maintaining a total base number (TBN) above about 3 mg KOH/g for a lubricant for a diesel engine for greater than about 184 days. The method includes supplying as the lubricant, a lubricant composition comprising a sulfonate detergent having a TBN ranging from about 20 to about 100 and a phenate detergent having a TBN ranging from about 200 to about 350 and an antioxidant selected from the group consisting essentially of hindered phenolic derivatives of C | 2011-01-06 |
20110003723 | LUBRICANT COMPOSITION - A lubricating oil composition is used in an internal combustion engine that uses a fuel containing at least one fat and oil of natural fat and oil, hydrotreated natural fat and oil, transesterified natural fat and oil and hydrotreated transesterified natural fat and oil. A sulfur compound containing at least one —C—S—C-bond is added to base oil. A content of sulfur contained in the —C—S—C-bond is 0.3 mass % or less based on a total amount of the compound. | 2011-01-06 |
20110003724 | LUBRICATING COMPOSITIONS FOR TRANSMISSIONS - The invention relates to a method for improving properties of protection against spalling of transmission lubricating compositions containing sulphur-containing and sulfur-phosphorous compounds comprising a step for adding into the initial transmission lubricating composition, compounds (c) reducing by at least 5% the active sulfur mass content, as measured by the ASTM D1662 standard, in the final composition. | 2011-01-06 |
20110003725 | LUBRICANT OIL COMPOSITION - The present invention provides a lubricating oil composition comprising:
| 2011-01-06 |
20110003726 | LOW TEMPERATURE PERFORMANCE LUBRICATING OIL DETERGENTS AND METHOD OF MAKING THE SAME - The present invention is directed to a method for preparing an unsulfurized, carboxylate-containing additive for lubricating oils and the product produced by said method, wherein said method comprises a) neutralization of a mixture of at least two alkyl phenols using an alkaline earth base in the presence of a promoter, to produce a mixture of alkyl phenates, wherein the mixture of at least two alkyl phenols comprises at least a first alkyl phenol wherein the alkyl group is derived from an isomerized alpha olefin and a second alkyl phenol wherein the alkyl group is derived from a branched chain olefin; (b) carboxylation of the mixture of alkyl phenates obtained in step (a) using carbon dioxide under carboxylation conditions sufficient to convert at least 20 mole % of the starting alkyl phenols to alkyl salicylate; and (c) removal of at least about 10% of the starting mixture of at least two alkyl phenols from the product produced in step (b) to produce said additive. | 2011-01-06 |
20110003727 | HYDROGENATED AND PARTIALLY HYDROGENATED HEAT-BODIED OILS AND USES THEREOF - The present disclosure presents materials comprising hydrogenated and/or partially hydrogenated polymerized vegetable oils. Non-limiting applications of the polymerized oils, including coatings, binders, blends, and greases are presented. Methods for forming these materials are also disclosed. | 2011-01-06 |
20110003728 | Cleaning composition - A rifle bore cleaning mixture of 2.4 by volume of Sweet's to 1 of Kroil to produce an approximate compound that is 70% by volume of Sweet's and 30% by volume of Kroil without combining any further additives with the mixture. | 2011-01-06 |
20110003729 | Novel fungal protease and use thereof - The present invention is related to a fungal serine protease enzyme, which comprises an amino acid sequence of the mature Fe_RF6318 enzyme having an amino acid sequence of SEQ ID NO: 15. The serine protease is obtainable from | 2011-01-06 |
20110003730 | SUBTILASES - The present invention relates to novel JP170 like subtilases from wild-type bacteria, hybrids thereof and to methods of construction and production of these proteases. Further, the present invention relates to use of the claimed subtilases in detergents, such as a laundry or an automatic dishwashing detergent. | 2011-01-06 |
20110003731 | Fragrance Delivery - A substrate such as a fabric may be provided with a fragrance during washing or rinsing process by the addition to the wash water of a free-flowing solid fragrance-providing composition that comprises a fragrance deposited on a particulate carrier along with a water soluble salt of an alkali metal or an alkaline earth metal. | 2011-01-06 |
20110003732 | Aromas Kit - An Aromas kit uses containers of certain discrete molecules to provide odors suitable for an olfactory education of wine properties. The disclosed molecules may be found within certain wines and provide a useful olfactory reference when smelling a finished wine sample, even when the wine sample contains a myriad of other conflicting or competing molecule smells. | 2011-01-06 |
20110003733 | RECONSTITUTED SURFACTANT COMPOSITION CONTAINING ANALOGS OF SURFACTANT PROTEIN B (SP-B) AND SURFACTANT PROTEIN C (SP-C) - Reconstituted pulmonary surfactants comprising a lipid carrier, a combination of polypeptide analog of the native surfactant protein SP-C with a particular polypeptide analog of the native surfactant protein SP-B may be used for the treatment or prophylaxis of RDS and other respiratory disorders. | 2011-01-06 |
20110003734 | PROTEINS AND POLYNUCLEOTIDES OF VIBRIO CHOLERAE - Therapeutic, diagnostic and environmental monitoring methods employing proteins encoded by the rbmBCDEF gene cluster and by bap1. | 2011-01-06 |
20110003735 | PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV INFECTION - This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections. | 2011-01-06 |
20110003736 | PESTICIDAL PROTEINS - The subject invention concerns new classes of pesticidally active proteins and the polynucleotide sequences that encode these proteins. In preferred embodiments, these pesticidal proteins have molecular weights of approximately 40-50 kDa and of approximately 10-15 kDa. | 2011-01-06 |
20110003737 | AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF - Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention. | 2011-01-06 |
20110003738 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF - Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention. | 2011-01-06 |
20110003739 | AZINONE-SUBSTITUTED AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF - Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention. | 2011-01-06 |
20110003740 | INSULIN SENSITISERS AND METHODS OF TREATMENT - The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods. | 2011-01-06 |
20110003741 | NOVEL NEURTURIN CONJUGATES FOR PHARMACEUTICAL USE - The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability. | 2011-01-06 |
20110003742 | Naphthalimide Dosing by N-Acetyl Transferase Genotyping - The present invention provides methods for dosing patients with naphthalimides, including amonafide, amonafide salts, and analogs thereof based on N-acetyl transferase genotyping. The invention also provides methods for dosing the amount of granulocyte colony stimulating factor (GCSF) used in combination with naphthalimide to prevent or modulate leukocytopenia. | 2011-01-06 |
20110003743 | STEM CELL DERIVED FACTORS FOR TREATING PATHOLOGIC CONDITIONS - A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic condtions. | 2011-01-06 |
20110003744 | Glycopegylated Erythropoietin Formulations - The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates. | 2011-01-06 |
20110003745 | GRANULATE-MATRIX - Composition comprising a granulate selected from the group consisting of autogenous bone material, bone/bone like material from natural sources, synthetic materials and mixtures thereof and a matrix obtainable by a self selective reaction of at least two precursors A and B in the presence of water. A kit for preparing said composition is also described. | 2011-01-06 |
20110003746 | Protein variants - IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16, 25, 49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder characterized by dysregulation of the GH/IGF axis in a mammal, such as a renal disorder. | 2011-01-06 |
20110003747 | USE OF NRF2 INDUCERS TO TREAT EPIDERMOLYSIS BULLOSA SIMPLEX AND RELATED DISEASES - The present invention relates to methods and compositions for the prevention and treatment of keratin-based skin diseases. In particular, the application describes compositions and methods of treating a patient suffering from skin blistering comprising the use of phase II enzyme inducers. | 2011-01-06 |
20110003748 | Method of treatment and compositions of D-chiro inositol and phosphates thereof - The present invention relates to the use of D-chiroinositol or a phosphate thereof in combination with folate for the reduction or prevention of congenital deformations such as anorectal malformations, neural tube defects, cleft-lip, cleft palate, and other birth defects. The invention further relates to the use of D-chiroinositol or a phosphate thereof in quieting or preventing the sensitivity of breast tissue to estrogenic, progestogenic, and or anti-androgenic insult, whether from environmental, dietary, or medicinal sources. Co-therapies as well as combination products of D-chiro-inositol (or a phosphate thereof) with at least one of (a) a folate source and (b) one or more of an estrogenic substance, a progestogenic substance, and/or an antiandrogenic substance are also claimed. | 2011-01-06 |
20110003749 | USE OF SOMATOSTATIN OR ONE OF ITS ANALOGUES FOR PREPARING A MEDICAMENT INTENDED TO REGULATE THE OVARIAN FOLLICULAR RESERVE IN NON-MENOPAUSAL WOMEN - The invention primarily relates to the use of somatostatin or one of the agonistic analogs thereof for producing a medicament serving to regulate the ovarian follicular reserve and, in particular, to reduce the depletion of the ovarian follicular reserve over time in non-menopausal women or to the use of an antagonistic analog of somatostatin for producing a medicament serving to accelerate the start of growing of quiescent follicles in non-menopausal women. The invention also relates to in vitro applications of somatostatin and of agonistic and antagonistic analogs thereof. | 2011-01-06 |
20110003750 | HUMAN 3 RELAXIN - Human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues having a modified A chain and/or a modified B chain are described. Also described are nucleic acid sequences encoded human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues. Also described are methods for the treatment of conditions responsive to administration of H3 relaxin or analogues thereof. | 2011-01-06 |
20110003751 | Novel Immunoregulatory Peptides, Compositions and Uses Thereof - A biologically active peptide, of Formula (1) [X-L-γ-Glu-Trp-Y], a novel pharmaceutical composition containing the peptide, a method for preparing the peptide and uses of the peptide are disclosed. | 2011-01-06 |
20110003752 | New Blood Coagulation Factor Inhibitors - The invention relates to novel compounds with formula (I) X | 2011-01-06 |
20110003753 | COMPOSITIONS AND METHODS FOR DISRUPTING THE FUNCTION OF THE TRANSCRIPTIONAL REPRESSOR COMPONENT Sin3A-PAH2 DOMAIN TO INDUCE DIFFERENTIATION AND GROWTH INHIBITION IN BREAST CANCER - The present invention relates, generally, to compositions for treating breast cancer, use of the compositions to sensitize breast cancer cells to treatment, and methods for treating breast cancer by administering the compositions. The compositions comprise peptides derived from the mSin3A interaction domain (SID) and derivatives thereof, as well as small molecule inhibitors (SMIs) capable of interfering with interactions between SID and the paired amphipathic helix domain 2 (PAH2) domain of the transcription repressor Sin3A. The present invention further relates to compositions for treating triple-negative breast cancer, use of the compositions to render the breast cancer cells susceptible to treatment using hormonal therapies and HER2-based therapies, and methods for treating triple-negative breast cancer by administering the compositions. | 2011-01-06 |
20110003754 | Peptide-Conjugated Oligonucleotide Therapeutic and Method of Making and Using Same - Conjugates for the efficient delivery of sequence-specific antisense to cells of a selected type for the inhibition of a target protein have the general formula: | 2011-01-06 |
20110003755 | Tumor Endothelial Marker 5-alpha Molecules and Uses Thereof - The present invention provides Tumor Endothelial Marker 5α (TEM5α) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM5α polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, or prevention of diseases, disorders, and conditions associated with TEM5α polypeptides. | 2011-01-06 |
20110003756 | C5a Receptor Antagonists - The present invention is related to a compound, preferably a C5a receptor antagonist, having the following structure: | 2011-01-06 |
20110003757 | PHARMACEUTICAL COMPOSITIONS FOR TREATING FATTY LIVER DISEASE - The present invention provides a pharmaceutical composition useful as a therapeutic agent for fatty liver disease. A pharmaceutical composition, which comprises (1S)-1,5-anhydro-1-[5-(azulen-2-ylmethyl)-2-hydroxyphenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, (1S)-1,5-anhydro-1-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, or alternatively, (1S)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, more specifically such a pharmaceutical composition for treating fatty liver disease, such as nonalcoholic fatty liver disease in one embodiment, or nonalcoholic simple fatty liver and/or nonalcoholic steatohepatitis in another embodiment. | 2011-01-06 |
20110003758 | Inhibitors of Glycolysis Useful In the Treatment of Brain Tumors - Provided herein are methods of treating brain tumors by administering a therapeutically effective amount of a compound of the Formulas I or II to a patient in need thereof. | 2011-01-06 |
20110003759 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS - The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I | 2011-01-06 |
20110003760 | ABNORMAL PROTEIN REMOVING METHOD - A method for treating symptoms or diseases associated with accumulation of abnormal protein in the body includes administrating to a subject desiring such treatment a composition containing silybin and soybean saponin in an amount effective to reduce or remove abnormal protein produced in the body. | 2011-01-06 |
20110003761 | BIOLOGICALLY ACTIVE EXTRACT FROM DENDROBIUM PLANT, USE THEREOF AND PROCESS FOR PREPARING THE SAME - A substance having the following formula is provided. | 2011-01-06 |
20110003762 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OBESITY, INSULIN RELATED DISEASES AND HYPERCHOLESTEROLEMIA - A process of enhancing insulin excretion in a subject includes administering to the subject a polyphenol active ingredient. The polyphenol active ingredient is a purified cyanidin-3-glycoside alone or purified cyanidin alone. The pharmaceutically acceptable carrier is administered with the polyphenol active ingredient. | 2011-01-06 |
20110003763 | AVERMECTIN/BENZOYL PEROXIDE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA - Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and benzoyl peroxide, are useful for treating afflictions of the skin, especially rosacea. | 2011-01-06 |
20110003764 | Methods for Treatment of HIV or Malaria Using Combinations of Chloroquine and Protease Inhibitors - The present invention relates to a drug combination capable of conferring therapeutic benefits in the treatment of both AIDS and malaria. In particular, it relates to a drug combination including at least one quinolinic antimalarial compound such as chloroquine or hydroxychloroquine, and at least one inhibitor of the Human Immunodeficiency Virus (HIV) protease enzyme. This drug combination is capable of inhibiting the replication of both HIV and | 2011-01-06 |
20110003765 | SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS - The present invention provides substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters and pharmaceutical compositions containing the same that are selective agonists of A | 2011-01-06 |
20110003766 | ALKOXY-CARBONYL-AMINO-ALKYNYL-ADENOSINE COMPOUNDS AND DERIVATIVES THEREOF AS A2AR AGONISTS - Provided herein are alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of A | 2011-01-06 |
20110003767 | Inhibitors of Acetyl-CoA Carboxylase for Treatment of Neuronal Hypometabolism - This invention relates to methods of using inhibitors of the enzyme acetyl-CoA carboxylase (ACC) for the treatment, prevention, inhibition or alleviation of diseases associated with neuronal hypometabolism and/or loss of cognitive function caused by reduced neuronal metabolism such as, for example, Age Associated Memory Impairment (AAMI), Mild Cognitive Impairment (MCI), Alzheimer's disease, Parkinson's disease, Friedreich's Ataxia (FRDA), GLUT1-deficient Epilepsy, Leprechaunism and Rabson-Mendenhall Syndrome, Coronary Arterial Bypass Graft (CABG) dementia, anesthesia induced memory loss, Huntington's disease and many others. | 2011-01-06 |
20110003768 | PREBIOTIC COMPOSITIONS - The present invention concerns nutritional compositions comprising oligosaccharides for controlling inflammatory bowel disease and related disorders, such as diarrhoea and constipation. | 2011-01-06 |
20110003769 | ANTI-AGING COMPOSITION FOR EXTERNAL USE COMPRISING LOW AND HIGH MOLECULAR WEIGHT HYALURONIC ACIDS AND THE POLYSACCHARIDES EXTRACTED FROM ROOT BARK OF ULMUS DAVIDIANA - Disclosed is an anti-aging composition for external use on skin, which includes low-molecular weight hyaluronic acids, high-molecular weight hyaluronic acids and polysaccharides extracted from root bark of | 2011-01-06 |
20110003770 | METHOD AND PHARMACEUTICAL TO TREAT SPINAL DISCS - Methods for reducing chronic pain caused by a disrupted spinal disc are described. In one method, a physiologically acceptable amount of an injectable is injected into the disc. The injectable is obtained from a stock solution comprising chondroitin sulphate, glucosamine HCl, aqueous solution of dextrose; sodium carboxymethylcellulose, and a buffer substance in quantity to bring the pH of the stock solution to a value above about 6.0. Water is also added to dilute the stock solution. The stock solution may further comprise an anesthetic such as bupivicaine. | 2011-01-06 |
20110003771 | Wood Preservative Composition - A wood preservative composition comprising a mixture of a fungicide which is a combination of a boric acid ester, which is soluble in an organic solvent and has a sterically hindered di-alcohol or tri-alcohol group, such as trihexylene glycol biborate, an organo-iodine compound, a triazole, and a synthetic pyrethroid insecticide, said fungicide and the insecticide being present in a sufficient amount that wood treated with the wood treatment material contains fungicide and insecticide in an amount of about 1 ppm to 5000 ppm, based on the weight of the wood after treatment. | 2011-01-06 |
20110003772 | USE OF SPHINGOLIPIDS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS, INSULIN RESISTANCE AND METABOLIC SYNDROME - The present invention relates to the use of sphingolipids for the preparation of a food item, a food supplement and/or a medicament for the treatment of insulin resistance, diabetes mellitus type 2 and/or metabolic syndrome. In particular, the invention relates to the use of a sphingolipid with the general formula (I): | 2011-01-06 |
20110003773 | USING FULLERENES TO ENHANCE AND STIMULATE HAIR GROWTH - Described herein are methods for treating lack of hair growth or a reduction or loss of existing hair by stimulating and/or restoring hair growth, or preventing hair loss. The methods comprise administering to a subject in need thereof a therapeutically effective amount of a fullerene. | 2011-01-06 |
20110003774 | COMPOUNDS HAVING ANTI-PROLIFERATIVE PROPERTIES - There is provided a method of inhibiting the occurrence of one of more of the following conditions:—the proliferation of monocytes/macrophages; or—the proliferation of smooth muscle cells; or—the expression of CD36 receptors; or—the uptake of oxidized LDL, the method comprising the step of administering an effective amount of one or more phosphate derivatives of one or more electron transfer agents. | 2011-01-06 |
20110003775 | COMPOSITION AND METHOD FOR PROMOTING SURVIVAL OF AGED BASAL FOREBRAIN CHOLINERGIC NEURON LEADING TO PROVENTION AND TREATMENT OF AGE-RELATED NEURODEGENERATIVE DISORDER - A method of treating a subject and preventing in a subject age-dependent basal forebrain cholinergic dysfunction related neurodegenerative disorders, comprising: administering a lipid composition comprising a therapeutically effective amount of highly enriched 1-acyl chains/2-docosahexaenoic acid containing molecular species of highly pure phospholipids to promote survival of aged basal forebrain cholinergic neurons, the phospholipids selected from the group consisting of phosphatidylserine, phosphatidylethanolamine, and phosphatidyl-monomethylethanolamine. A composition for treating a subject and preventing in a subject age-dependent basal forebrain cholinergic dysfunction related neurodegenerative disorders, the composition comprising: a lipid composition comprising: a therapeutically effective amount of highly enriched 1-acyl chains/2-docosahexaenoic acid containing molecular species of highly pure phospholipids to promote survival of aged basal forebrain cholinergic neurons, the phospholipids selected from the group consisting of phosphatidylserine, phosphatidylethanolamine, and phosphatidyl-monomethylethanolamine. A process for preparing a lipid composition comprising a therapeutically amount of natural source-based highly enriched 1-acyl chains/2-docosahexaenoic acid containing molecular species of highly pure phosphatidylserine to promote survival of aged basal forebrain cholinergic neurons; the process comprising: purifying a natural source-based phosphatidylcholine by silica chromatography; obtaining a related lysophosphatidylserine species by phospholipase A2 catalysis of transphosphatidylated natural source-based phosphatidylserine species; acylating the lysophosphatidylserine species with natural docosahexaenoic acid to form 1-acyl chains/2-docosahexaenoic acid containing phosphatidylserine species; and purifying the 1-acyl cgains/2-docosahexaenoic acid containing phosphatidylserine species by silica chromatography. | 2011-01-06 |
20110003776 | TETRAHYDROPYRANONAPHTHYRIDINES DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC TREATMENT THEREOF - This invention relates to tetrahydropyranonaphthyridines derivatives having formula (III) or IV: | 2011-01-06 |
20110003777 | Methods of Treatment Employing Prolonged Continuous Infusion of Belinostat - The present invention relates generally to the treatment of diseases and disorders that are mediated by histone deacetylase (HDAC), for example, cancer, with Belinostat™ (also known as (E)-N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide; PXD101; and PX 105684), and more particularly, to improvement treatments of such diseases (for example, cancers, for example, leukemias), which employ prolonged continuous infusion (e.g., prolonged continuous intravenous infusion) of Belinostat™. | 2011-01-06 |
20110003778 | MINERALCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS - The present invention provides the use of mineralocorticoid receptor antagonists for preparing a medicament for the treatment of endometriosis. | 2011-01-06 |
20110003779 | 15, 16-METHYLENE-17-(1'-PROPENYL)-17,3'-OXIDOESTRA-4-EN-3-ONE DERIVATIVE , USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE - The invention relates to 15,16-methylene-17-(1′-propenyl)-17-3′-oxidoestra-4-en-3-one derivatives with the general chemical formula I, where the Z, R | 2011-01-06 |
20110003780 | HYDROGEN CHLORIDE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND AND A PROCESS FOR THE PRODUCTION THEREOF - The present invention relates to the compound of the Formula I: | 2011-01-06 |
20110003781 | Non-Sedating Antihistamine Injection Formulations and Methods of Use Thereof - Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute allergic reactions including anaphylaxis with the compositions are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage forms. In other embodiments, the non-sedating or second and third generation antihistamine injectable formulations are therapeutically equivalent to diphenhydramine injectable formulations and/or are more effective than placebo. In other embodiments, a non-sedating antihistamine injectable composition is delivered by an autoinjector. | 2011-01-06 |
20110003782 | 23-Substituted Bile Acids as TGR5 Modulators and Methods of Use Thereof - The invention relates to compounds of Formula A: (A) or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including obesity, insulin sensitivity, inflammation, cholestasis, and bile desaturation. | 2011-01-06 |
20110003783 | NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND RELATED METHODS THEREFOR - An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day “nocturnally,” that is in the evening or at night, | 2011-01-06 |
20110003784 | Opsin-binding ligands, compositions and methods of use - Compounds and compositions of said compounds along with methods of use of compounds are disclosed for treating ophthalmic conditions related to mislocalization of opsin proteins, the misfolding of mutant opsin proteins and the production of toxic visual cycle products that accumulate in the eye. Compounds and compositions useful in the these methods, either alone or in combination with other therapeutic agents, are also described. | 2011-01-06 |
20110003785 | Fused Thiazole Derivatives As Kinase Inhibitors - A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 2011-01-06 |
20110003786 | 2-Carboxamide Cycloamino Ureas - The present invention relates to compounds of formula I | 2011-01-06 |
20110003787 | NOVEL PHENYLPYRROLE DERIVATIVE - The present invention relates to a compound or a pharmacologically acceptable salt thereof having superior glucokinase activating activity, and is a compound represented by general formula (I), or pharmacologically acceptable salt thereof: | 2011-01-06 |
20110003788 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF - The present invention provides a compound having a superior Smo inhibitory activity and lower toxicity, which is sufficiently satisfactory as a pharmaceutical product. The present invention provides a compound represented by the formula (I) wherein ring A is 5- to 7-membered ring optionally having substituent(s), where substituents are optionally bonded to each other to form a ring; X is O, S or NR | 2011-01-06 |
20110003789 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES - The invention relates to antibacterial compounds of formula I | 2011-01-06 |
20110003790 | PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS - The invention provides a class of compounds of Formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET, TrkA, TrkB, TrkC, IGR-IR, AIk, c-FMS, or combinations thereof. | 2011-01-06 |
20110003791 | Cyclized Derivatives as EG-5 Inhibitors - The present invention relates to new substituted imidazole compounds have the following Formula (I) and to the pharmaceutically acceptable salts, esters, or prodrugs thereof, to compositions of the compounds together with pharmaceutically acceptable carriers, and to uses of the compounds: | 2011-01-06 |
20110003792 | ANTI-INFLAMMATORY AGENTS - The invention provides compounds, pharmaceutical compositions and uses of compounds and salts thereof of general formula (I), for the preparation of a medicament for treatment of an inflammatory disorder, | 2011-01-06 |
20110003793 | AZINONE-SUBSTITUTED AZEPINO[b]INDOLE AND PYRIDO-PYRROLO-AZEPINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF - Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention. | 2011-01-06 |
20110003794 | Naphthyridine Integrase Inhibitors - The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC. | 2011-01-06 |
20110003795 | Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands - The invention relates to substituted aromatic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions. | 2011-01-06 |
20110003796 | METHOD FOR THE TREATMENT OF PSYCHIC DISORDERS - Method for the treatment of psychiatric disorders, comprising administering to a subject in need thereof an amount of fatty acids and a suboptimal dose of at least one antidepressant. Wherein the fatty acid may be omega-3 (ω3), for example the docohexaenoic acid (DHA) and the eicosapentaenoic acid (EPA). The omega-3 fatty acid may be administered orally, in amounts that may be variable, for example in amounts between 0.15 and 1.00 g/kg/day. The antidepressant may be any antidepressant, preferably the antidepressant is fluoxetine or mirtazapine in sub-optimal doses. | 2011-01-06 |
20110003797 | HEXAHYDROCYCLOPENTYL[f]INDAZOLE CARBOXAMIDES AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS - The present invention is directed to hexahydrocyclopentyl[f]imidazole carboxamides and derivatives thereof as selective glucocorticoid receptor ligands useful for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included. | 2011-01-06 |
20110003798 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS - The invention provides a novel class of 2,7-naphthyridin derivatives; pharmaceutical compositions comprising such compounds and methods of using such compounds to treat o prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Syk, ZAP70, KDR, FMS, FLT*, c-Kit, RET, TrkA, TrkB, TrkC-GR-1R, Alk, c-FMS or combinations thereof. | 2011-01-06 |
20110003799 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS - The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3. | 2011-01-06 |
20110003800 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS - Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: | 2011-01-06 |
20110003801 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS - Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: | 2011-01-06 |
20110003802 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase - The invention provides N-cyclic sulfonamido compounds and salts of Formula I: | 2011-01-06 |
20110003803 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC, OTIC, OR NASAL INFECTIONS - The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections. | 2011-01-06 |
20110003804 | Oxazolidinones For the Treatment and/or Prophylaxis of Heart Failure - The present invention relates to the use of selective inhibitors of coagulation factor Xa, in particular of oxazolidinones of the formula (I), for the treatment and/or prophylaxis of heart failure and/or disorders related to heart failure as well as their use for the preparation of pharmaceutical drugs for the treatment and/or prophylaxis of heart failure and/or disorders related to heart failure. | 2011-01-06 |
20110003805 | CONCOMITANT DRUG - Provided is a combination drug. The present invention provides a pharmaceutical agent comprising (1) a HER2 inhibitor having a pyrrolopyrimidine skeleton or pyrazolopyrimidine skeleton, and (2) not less than one pharmaceutical agent selected from an mTOR inhibitor, a PI3 kinase inhibitor and a cMet inhibitor in combination. | 2011-01-06 |
20110003806 | Heteroaryls and uses thereof - This invention provides compounds of formula IA or IB: | 2011-01-06 |